These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 7426922

  • 21. Misonidazole enhancement of radiation-induced growth delay in rat rhabdomyosarcoma tumours exposed to accelerated carbon and neon ions.
    Tenforde TS, Curtis SB, Tenforde SD, Parr SS, Crabtree KE, Flynn MJ, Howard J, Lyman JT.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1981 Aug; 40(2):117-29. PubMed ID: 6974143
    [Abstract] [Full Text] [Related]

  • 22. The effects of misonidazole during continuous low dose rate irradiation.
    Fu KK, Hurst S, Begg AC, Brown JM.
    Cancer Clin Trials; 1980 Aug; 3(3):257-65. PubMed ID: 7438323
    [Abstract] [Full Text] [Related]

  • 23. Clinical experience with misonidazole.
    Dische S, Saunders MI.
    Br J Cancer Suppl; 1978 Jun; 3():311-3. PubMed ID: 277252
    [Abstract] [Full Text] [Related]

  • 24. Radical irradiation and misonidazole in the treatment of T2 grade III and T3 bladder cancer.
    Abratt RP, Sealy R, Tucker RD, Williams MA, Barnes DR, Johnson MB, Green JA, Cridland JS.
    Int J Radiat Oncol Biol Phys; 1983 May; 9(5):629-32. PubMed ID: 6853264
    [Abstract] [Full Text] [Related]

  • 25. Preliminary results of RTOG phase I/II study of misonidazole and radiation for bladder cancer.
    Mohiuddin M, Kramer S, Phillips T, Soberon M, Forgione H.
    Am J Clin Oncol; 1982 Oct; 5(5):551-4. PubMed ID: 7180834
    [Abstract] [Full Text] [Related]

  • 26. [Effect of even or uneven dose fractionation regime on murine squamous cell carcinoma with combined use of misonidazole].
    Yasunaga T, Takada C, Takahashi M, Okada S, Sakamoto K.
    Nihon Igaku Hoshasen Gakkai Zasshi; 1983 Oct 25; 43(10):1224-31. PubMed ID: 6672751
    [No Abstract] [Full Text] [Related]

  • 27. Radiosensitization in multifraction schedules. II. Greater sensitization by 2-nitroimidazoles than by oxygen.
    Taylor YC, Brown JM.
    Radiat Res; 1987 Oct 25; 112(1):134-45. PubMed ID: 3659294
    [Abstract] [Full Text] [Related]

  • 28. Pilot study of radiotherapy with misonidazole in head and neck cancer.
    Paterson IC, Dawes PJ, Henk JM, Moore JL.
    Clin Radiol; 1981 Mar 25; 32(2):225-9. PubMed ID: 7214840
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Clinical experiences with the radiation-sensitizing agent misonidazole].
    Kogelnik HD, Szepesi T, Kärcher KH, Seitz W.
    Strahlentherapie Sonderb; 1978 Mar 25; 75():115-9. PubMed ID: 162327
    [No Abstract] [Full Text] [Related]

  • 31. Radiosensitizing effect of misonidazole in fractionated gamma-ray treatment of a human malignant melanoma grown in athymic nude mice.
    Rofstad EK, Brustad T.
    Br J Radiol; 1979 May 25; 52(617):393-7. PubMed ID: 444837
    [Abstract] [Full Text] [Related]

  • 32. The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity.
    Jones DH, Bleehen NM, Workman P, Smith NC.
    Br J Radiol; 1983 Nov 25; 56(671):865-70. PubMed ID: 6626878
    [Abstract] [Full Text] [Related]

  • 33. On the sensitisation of skin radionecrosis in mice by misonidazole at low doses.
    Hendry JH, Sutton ML.
    Br J Radiol; 1984 Jun 25; 57(678):507-14. PubMed ID: 6722448
    [Abstract] [Full Text] [Related]

  • 34. Combination of misonidazole and m-AMSA: effects on radiation sensitivity and toxicity in E. coli.
    Roberts PB.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1982 Aug 25; 42(2):173-83. PubMed ID: 6752069
    [Abstract] [Full Text] [Related]

  • 35. Effect of hypoxia on the cytotoxicity of misonidazole in HELA S3 cells in vitro.
    Ohizumi Y, Shibata C, Mori T.
    Gan; 1980 Jun 25; 71(3):319-24. PubMed ID: 7418978
    [Abstract] [Full Text] [Related]

  • 36. Misonidazole with small dose fractions in an experimental osteosarcoma.
    van Putten LM, Smink T.
    Br J Cancer Suppl; 1978 Jun 25; 3():246-9. PubMed ID: 277240
    [Abstract] [Full Text] [Related]

  • 37. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
    Hoskin PJ, Saunders MI, Dische S.
    Cancer; 1999 Oct 01; 86(7):1322-8. PubMed ID: 10506720
    [Abstract] [Full Text] [Related]

  • 38. The use of misonidazole in association with a three-fractions per day regimen in advanced head and neck epidermoid cancer. A pilot study.
    Awwad HK, Barsoum M, El Merzabani M, Omar S, El Badawy S, Ezzat S, El Baki HA, Zaki A.
    Am J Clin Oncol; 1983 Feb 01; 6(1):91-7. PubMed ID: 6301258
    [Abstract] [Full Text] [Related]

  • 39. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
    Phillips TL, Wasserman TH, Johnson RJ, Levin VA, VanRaalte G.
    Cancer; 1981 Oct 15; 48(8):1697-704. PubMed ID: 6269723
    [Abstract] [Full Text] [Related]

  • 40. Effects of oxygen and misonidazole on cell transformation and cell killing in C3H 10T1/2 cells by X rays in vitro.
    Borsa J, Sargent MD, Einspenner M, Azzam EI, Raaphorst GP.
    Radiat Res; 1984 Oct 15; 100(1):96-103. PubMed ID: 6494435
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.